Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Chronic Eye Diseases: Exploring Sustained-Release Treatments

By: Thomas A. Albini, MD; and Nathan M. Radcliffe, MD

Webinar Credits: 1

Expiration Date: Wednesday, September 30, 2020
Release Date: September 2019

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Assess data from the latest clinical studies on sustained-release devices and methods.
  • Describe the benefits and challenges of sustained-release devices and methods versus conventional treatments.
  • Identify the various sustained-release devices on the market and in the pipeline.
  • Evaluate how to incorporate sustained-release devices into treatment regimens.

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

The following faculty/staff members have the following financial relationships with commercial interests:

Thomas A. Albini, MD
Dr. Albini has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Speaker’s Bureau/Grant/Research/Support:  Alimera, Allergan, Bausch + Lomb, Eyepoint, Genentech, and Regenexbio. Alimera, Allergan, Bausch + Lomb, Eyepoint, Genentech, Regenexbio; Investigator in MUST and MACTEL study.

Nathan M. Radcliffe, MD
Dr. Radcliffe has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Alcon, Alimera, Allergan, Bausch & Lomb, Ellex, Endo Optiks, Equinox Glaukos Reichert, Iridex, Lumenis, New World Medical, Novartis, and Sight Sciences. Speaker’s Bureau: Aerie, Alcon, Alimera Allergan, Bausch & Lomb, Carl Zeiss Meditec, CATS Ellex, Endo Optiks, Equinox, Eyenovia, Eyepoint, Glaukos, Iridex, Ivantis, Lumenis, New World Medical, Novartis Ocular Science Omeros, Reichert, Sight Sciences, Shire, Thea, Pharmaceuticals

Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

 

Disclaimer

Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Allergan, or EyePoint Pharmaceuticals.

Pretest

  • A. 1B. 2C. 3D. 4E. 5
  • A.1B. 2C. 3D. 4E. 5

Video Resources

Chronic Eye Diseases: Exploring Sustained-Release Treatments

Next

Test

Instructions

Step 1 of 3

33%
  • AgreeNeutralDisagree
    Assess data from the latest clinical studies on sustained-release devices and methods.
    Describe the benefits and challenges of sustained-release devices and methods versus conventional treatments.
    Identify the various sustained-release devices on the market and in the pipeline.
    Evaluate how to incorporate sustained-release devices into treatment regimens.
Back